---
freshness:
  last-reviewed: 2025-01-28
  data-year: 2025
  review-cycle: 6
  sections:
    - name: "Phase 1: Immediate Reforms"
      data-year: 2025
    - name: "Phase 2: Systemic Transformation"
      data-year: 2025
    - name: "Phase 3: Full System Redesign"
      data-year: 2025
    - name: "Political Landscape Assessment"
      data-year: 2025
notes:
  - Update after 119th Congress legislative action on SUPPORT Act reauthorization.
  - Track DEA methadone pharmacy dispensing final rule.
  - Monitor opioid settlement fund deployment milestones.
  - Flag any changes to Medicaid expansion status in non-expansion states.
  - Update political landscape after 2026 midterm elections.
sources:
  count: 18
  verified: 2025-01-28
  broken: 0
---

# Drug Treatment: Implementation Roadmap

## Overview

Transforming America's drug treatment system requires a phased approach that sequences reforms based on political viability, implementation complexity, and expected impact. This roadmap prioritizes actions that can save lives immediately while building toward the structural changes needed for a comprehensive, evidence-based treatment system.

---

## Phase 1: Immediate Reforms (Years 1-2)

These actions can be taken through executive authority, regulatory action, and politically viable legislation. They require minimal new appropriations and address the most urgent access gaps.

### Priority Actions

| Priority | Action | Mechanism | KPI | Lead Entity |
|----------|--------|-----------|-----|-------------|
| 1 | Finalize pharmacy-based methadone dispensing | DEA rulemaking (proposed 2024) | Pharmacies certified to dispense; patients served | DEA, SAMHSA |
| 2 | Eliminate prior authorization for all FDA-approved MOUD | CMS mandate for Medicare/Medicaid; state insurance regulators | PA denial rate drops from 29% to <5% | CMS, state regulators |
| 3 | Expand buprenorphine prescribing through practice support | SAMHSA-funded mentoring (Project ECHO model) | Active prescribers increase from 130K to 250K | SAMHSA, HRSA |
| 4 | Permanent telehealth for SUD treatment | DEA rulemaking; Ryan Haight Act update | Telehealth MOUD visits maintained at COVID-era levels | DEA, Congress |
| 5 | Mandate MOUD in all federal prisons | BOP directive | MOUD availability in 100% of federal facilities (from ~50%) | DOJ, BOP |
| 6 | Fund ED-initiated buprenorphine programs | SAMHSA grants; CMS reimbursement codes | EDs offering buprenorphine: from 18% to 40% | SAMHSA, CMS |
| 7 | Launch opioid settlement fund accountability framework | Interagency guidance; model state legislation | Public reporting in all 50 states | DOJ, ONDCP |
| 8 | Strengthen MHPAEA enforcement | DOL enforcement division expansion | Parity investigations triple from baseline | DOL, HHS |

### Year 1 Milestones

| Quarter | Milestone | Measurable Outcome |
|---------|-----------|-------------------|
| Q1 | DEA finalizes pharmacy methadone rule | Final rule published in Federal Register |
| Q1 | CMS eliminates prior authorization for buprenorphine and methadone in Medicare/Medicaid | CMS guidance issued |
| Q2 | SAMHSA launches national ECHO-based buprenorphine mentoring program | 500 new prescribers enrolled |
| Q2 | BOP issues directive for MOUD in all federal prisons | Implementation plan published |
| Q3 | First pharmacies dispense methadone for OUD | 100 pharmacies certified |
| Q3 | SAMHSA distributes $200M for ED buprenorphine initiation | Grants awarded to 300+ hospitals |
| Q4 | DOL expands MHPAEA enforcement team | 50 new investigators hired |
| Q4 | Opioid settlement transparency framework published | All states with reporting requirements |

### Year 2 Milestones

| Quarter | Milestone | Measurable Outcome |
|---------|-----------|-------------------|
| Q1 | 1,000 pharmacies dispensing methadone | 50,000 new patients accessing methadone |
| Q1 | DEA finalizes permanent telehealth prescribing rules | Telehealth SUD visits stabilized |
| Q2 | Active buprenorphine prescribers reach 200,000 | 400,000 additional patients receiving buprenorphine |
| Q2 | All federal prisons offering MOUD | 25,000 incarcerated patients receiving MOUD |
| Q3 | 35% of EDs offering buprenorphine initiation | 50,000 additional patients initiated in EDs |
| Q4 | 300+ MHPAEA enforcement actions completed | Measurable reduction in parity violations |

**Phase 1 Goal:** Close the most acute treatment access gaps through regulatory reform and enforcement. Target: increase the national treatment rate from 24% to 32% within two years.

---

## Phase 2: Systemic Transformation (Years 3-5)

This phase requires congressional action, sustained appropriations, and state-level implementation. It addresses workforce shortages, financing gaps, and system fragmentation.

### Priority Actions

| Priority | Action | Mechanism | KPI | Estimated Cost (Annual) |
|----------|--------|-----------|-----|----------------------:|
| 1 | Reauthorize and expand SUPPORT Act | Legislation (119th or 120th Congress) | All expiring provisions renewed plus new authorities | $2 billion |
| 2 | Double SAPT Block Grant | Appropriations ($1.86B to $3.5B) | Block grant per capita increase in all states | $1.64 billion (new) |
| 3 | Establish national treatment quality standards | SAMHSA rulemaking; block grant conditions | 80% of facilities meet minimum EBP standards | $100 million |
| 4 | Expand CCBHC model to all states | Legislation; CMS implementation | 500 new CCBHCs; integrated SUD/MH care in all states | $1 billion |
| 5 | Addiction medicine workforce expansion | GME funding; loan repayment; training grants | Double addiction medicine fellows; 40K new counselors | $500 million |
| 6 | National contingency management expansion | CMS waiver authority; SAMHSA guidance | Medicaid CM coverage in 25+ states | $300 million |
| 7 | Recovery housing investment | Federal grant program; tax credits | 50,000 new recovery housing beds | $500 million |
| 8 | Criminal justice MOUD mandate for state prisons | Block grant conditions; model legislation | MOUD available in 50% of state prisons | $400 million |
| 9 | Medicaid SUD benefit enhancement | CMS guidance; 1115 waiver expansion | All Medicaid programs cover full SUD continuum | $2 billion |
| 10 | National anti-stigma campaign | SAMHSA + Ad Council partnership | Measurable shift in public attitudes | $50 million |

### Key Legislative Package: "Treatment Access and Recovery Act"

**Core provisions:**

| Title | Content | Impact |
|-------|---------|--------|
| Title I: Medication Access | Codify pharmacy-based methadone; permanent telehealth; remove remaining regulatory barriers | 2+ million additional patients accessing MOUD |
| Title II: Treatment Quality | National quality standards; outcome measurement mandate; accreditation reform | 80% of facilities meeting EBP standards |
| Title III: Workforce | GME expansion; loan repayment; peer specialist standards; counselor compensation | 40,000 new SUD professionals |
| Title IV: Financing | Block grant increase; parity enforcement; Medicaid enhancement | $5 billion in new annual treatment funding |
| Title V: Recovery | Recovery housing; employment support; ROSC implementation | 50,000 new recovery housing beds |
| Title VI: Criminal Justice | MOUD mandate in corrections; reentry programs; LEAD expansion | MOUD in all federal/state prisons |
| Title VII: Research | NIDA research expansion; implementation science; stimulant medication development | New treatments and delivery models |

### Year 3-5 Milestones

| Year | Milestone | Target |
|------|-----------|--------|
| Year 3 | Treatment Access and Recovery Act introduced | Bipartisan support in both chambers |
| Year 3 | SAMHSA publishes national treatment quality standards | Public comment and finalization |
| Year 3 | First CCBHC expansion cohort launched | 100 new sites |
| Year 4 | Act passes and signed into law | Full authorization |
| Year 4 | Block grant increase begins | $2.5 billion first-year appropriation |
| Year 4 | Addiction medicine fellowship positions doubled | 200 new fellows per year |
| Year 4 | Contingency management in Medicaid: 15 states | 100,000 patients receiving CM |
| Year 5 | National quality standards effective | 80% facility compliance |
| Year 5 | 5,000 pharmacies dispensing methadone | 200,000 new methadone patients |
| Year 5 | MOUD available in 50% of state prisons | 200,000 incarcerated patients |

**Phase 2 Goal:** Build the legislative and institutional infrastructure for a comprehensive treatment system. Target: increase national treatment rate from 32% to 45%.

---

## Phase 3: Full System Redesign (Years 6-10)

This phase completes the transformation to a fully integrated, recovery-oriented system of care accessible to every American regardless of geography, income, or insurance status.

### Priority Actions

| Priority | Action | KPI | Target (Year 10) |
|----------|--------|-----|-------------------|
| 1 | Universal SUD treatment access | Treatment rate by state | No state below 40% treatment rate |
| 2 | Full primary care integration | PCPs screening/treating SUD | 30% of PCPs actively prescribing MOUD |
| 3 | Comprehensive criminal justice integration | MOUD in all facilities | 100% of prisons/jails offering MOUD |
| 4 | Recovery-oriented systems of care | ROSC implementation | All states with funded ROSC infrastructure |
| 5 | Methadone access parity with other nations | Pharmacy dispensing | 15,000 pharmacies dispensing methadone |
| 6 | Workforce adequacy | Provider-to-patient ratios | No state designated as SUD workforce shortage area |
| 7 | Full parity compliance | MHPAEA violations | Annual violation rate below 10% |
| 8 | Treatment quality standardization | Outcome reporting | 95% of facilities reporting standardized outcomes |
| 9 | Medicaid expansion complete | Coverage gap | Zero states with Medicaid coverage gap |
| 10 | Overdose mortality reduction | Annual deaths | 50% reduction from 2023 baseline |

### Long-Term Targets

| Metric | Current (2024) | Year 5 Target | Year 10 Target |
|--------|---------------|---------------|----------------|
| National treatment rate | 24% | 45% | 60% |
| Active buprenorphine prescribers | 130,000 | 300,000 | 500,000 |
| Pharmacies dispensing methadone | 0 | 5,000 | 15,000 |
| Facilities meeting quality standards | ~20% | 80% | 95% |
| Annual overdose deaths | 107,543 | 80,000 | 55,000 |
| MHPAEA compliance rate | ~50% | 75% | 90% |
| SUD counselor median salary | $48,520 | $60,000 | $72,000 |
| States with Medicaid expansion | 40 + DC | 45 + DC | 50 + DC |
| Prisons/jails offering MOUD | ~20% | 50% | 100% |
| EDs initiating buprenorphine | 18% | 50% | 80% |

**Phase 3 Goal:** A treatment system that is accessible, evidence-based, integrated, and recovery-oriented. The U.S. achieves treatment access rates comparable to peer nations (60%+) and reduces overdose mortality by half.

---

## Political Landscape Assessment

### Federal Political Dynamics

| Factor | Assessment | Impact on Roadmap |
|--------|-----------|-------------------|
| Bipartisan support for treatment | Moderate-Strong (opioid crisis crosses party lines) | Phase 1 regulatory actions viable regardless of party control |
| Congressional appetite for SUD spending | Mixed (competing priorities) | Phase 2 legislation requires sustained advocacy |
| DEA willingness to reform | Cautiously positive (methadone proposal) | Phase 1 regulatory reform feasible with political leadership |
| Administration orientation | Variable by president | Phase 1 executive actions depend on administration |
| Opioid settlement momentum | Strong | Creates funding and accountability pressure |

### State Political Dynamics

| State Category | Number | Strategy |
|---------------|--------|----------|
| "Champion" states (strong treatment infrastructure) | 10-12 | Model programs; evaluation; peer learning |
| "Progress" states (expanding access) | 15-20 | Technical assistance; 1115 waivers; block grant incentives |
| "Moderate" states (some reforms) | 10-15 | Evidence-based advocacy; settlement fund pressure |
| "Resistant" states (minimal treatment infrastructure) | 8-10 | Federal block grant conditions; Medicaid incentives |

### Key Political Risks

| Risk | Probability | Mitigation |
|------|------------|-----------|
| Political backlash against "enabling" narrative | Medium | Frame as public safety and cost-effectiveness |
| Federal spending constraints | High | Leverage opioid settlements; reframe treatment as investment |
| DEA delays on methadone rule | Medium | Congressional pressure; presidential directive |
| State resistance to federal standards | Medium | Block grant incentives rather than mandates |
| Pharmaceutical industry opposition to pricing reform | Medium | Separate treatment access from pricing debates |
| Election-cycle disruption | High | Establish bipartisan commission; permanent authorization |

---

## Implementation Dependencies

```text
Phase 1 (Regulatory)
├── Pharmacy methadone (DEA final rule)
├── Prior auth elimination (CMS guidance)
├── Telehealth permanence (DEA/Congress)
├── Buprenorphine mentoring (SAMHSA grants)
├── Federal prison MOUD (DOJ directive)
└── Parity enforcement (DOL staffing)
    │
    ├── Phase 2 (Legislative)
    │   ├── Treatment Access and Recovery Act
    │   │   ├── Block grant increase (appropriations)
    │   │   ├── Quality standards (SAMHSA rulemaking)
    │   │   ├── CCBHC expansion (CMS implementation)
    │   │   ├── Workforce pipeline (GME/training)
    │   │   └── Recovery infrastructure (grants/credits)
    │   │
    │   └── State implementation
    │       ├── 1115 waivers
    │       ├── Medicaid benefit design
    │       ├── Licensing reform
    │       └── Settlement fund deployment
    │
    └── Phase 3 (System Transformation)
        ├── Universal access infrastructure
        ├── Full primary care integration
        ├── ROSC in all states
        ├── Complete criminal justice integration
        └── Workforce adequacy achieved
```

---

## Cost Estimates

### Total Investment Required

| Phase | Annual New Federal Investment | Cumulative (Over Phase Period) |
|-------|------------------------------|-------------------------------|
| Phase 1 (Years 1-2) | $500 million | $1 billion |
| Phase 2 (Years 3-5) | $6 billion | $18 billion |
| Phase 3 (Years 6-10) | $8 billion | $40 billion |
| **Total over 10 years** | | **$59 billion** |

### Return on Investment

| Category | Annual Savings at Full Implementation (Year 10) |
|----------|------------------------------------------------|
| Reduced criminal justice costs | $18 billion |
| Reduced healthcare costs | $12 billion |
| Reduced lost productivity | $24 billion |
| Reduced premature mortality | $15 billion |
| **Total annual savings** | **$69 billion** |
| **Net annual return** | **$61 billion** |
| **ROI** | **~8:1** |

*Sources: NIDA cost-effectiveness data; CEA estimates; Surgeon General's Report, 2016*

---

## Document Navigation

| Previous | Next |
|----------|------|
| [Solutions](07-solutions.md) | [Resources](09-resources.md) |

**Section Navigation:**
[Overview](01-overview.md) | [Current State](02-current-state.md) | [History](03-history.md) | [Root Causes](04-root-causes.md) | [Stakeholders](05-stakeholders.md) | [Opposition](06-opposition.md) | [Solutions](07-solutions.md) | [Roadmap](08-roadmap.md) | [Resources](09-resources.md) | [Actions](10-actions.md) | [Legislation](11-legislation.md) | [Perspectives](12-perspectives.md)
